About Bio-Thera Solutions, Company

The company is a science-based, global biopharmaceutical company based in Guangzhou, China. Adhering to the concept of “innovation is only for life”, the company is committed to developing a new generation of innovative drugs and biosimilar drugs based on modern biological science research findings to treat tumors, autoimmune diseases, cardiovascular diseases, ophthalmology, and other major diseases that endanger human life or health. The company was officially listed and traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange in February 2020. The main business is R&D, production and sales of pharmaceuticals, and has an independent and complete R&D, procurement, production and commercialization system. Main products: BAT1406 Geleril, BAT1706 Prbeshi, BAT1806 Schrelli, BAT2094 (batifiban), BAT2506 (golimumab), BAT2206 (usinumab), BAT2306 (scarciumab), BAT4406F all-human anti-CD20 antibody, BAT8006 targeting folic acid receptor α (FRα). Corporate honors: Guangdong Antibody Drug Coupling Biomedical Engineering Laboratory (Guangdong Engineering Laboratory), Guangdong PhD Workstation, R&D facility construction of Baiaotai Biotechnology (Guangzhou) Co., Ltd., “Most Promising Company” for venture capital in Hong Kong, etc.